What plant is vasicinone derived from?

Vasicinone is primarily extracted from Adhatoda vasica (also called Malabar nut or Vasaka), a medicinal shrub widely used in Ayurvedic and Unani medicine. It is a quinazoline alkaloid that occurs alongside its biosynthetic precursor vasicine, and both compounds contribute to the plant's traditional use as a bronchial remedy. Smaller amounts have also been identified in other plants within the Acanthaceae family.

Is vasicinone the same as vasicine?

No, vasicinone and vasicine are distinct but structurally related quinazoline alkaloids; vasicinone is the oxidized form of vasicine, featuring a ketone group at the C-3 position that alters its pharmacological profile. Both compounds exhibit bronchodilatory properties, but vasicinone generally shows slightly stronger PDE inhibition in preclinical assays, while vasicine has more documented uterotonic activity. They often co-occur in Adhatoda vasica extracts, which complicates isolating the individual contributions of each compound in herbal preparations.

Can vasicinone help with asthma or COPD?

Preclinical studies suggest vasicinone may relieve bronchospasm by inhibiting phosphodiesterase enzymes and elevating cAMP in airway smooth muscle, mechanisms relevant to asthma and COPD management. However, no human clinical trials have confirmed these effects, and no regulatory body has approved vasicinone as a treatment for either condition. Individuals with asthma or COPD should not substitute vasicinone-containing supplements for prescribed bronchodilators or corticosteroids without explicit medical guidance.

Does vasicinone interact with any medications?

Vasicinone's PDE-inhibiting activity creates a theoretical additive interaction with bronchodilators such as theophylline and beta-2 agonists like salbutamol, potentially increasing cardiovascular side effects including palpitations and blood pressure changes. Its proposed MAO-B inhibitory activity suggests possible interactions with antidepressants (particularly MAOIs and SSRIs) and dopaminergic medications used in Parkinson's disease. These interactions have not been confirmed in clinical pharmacokinetic studies, so anyone taking prescription medications should consult a healthcare provider before using vasicinone-containing products.

What is the research status of vasicinone for Parkinson's disease?

Research into vasicinone for Parkinson's disease is at an early preclinical stage, based on studies using the MPTP neurotoxin mouse model, where vasicinone demonstrated reduced loss of dopaminergic neurons in the substantia nigra and attenuated oxidative stress biomarkers including ROS and lipid peroxidation products. Its proposed mechanism involves MAO-B inhibition—the same enzyme targeted by approved drugs like selegiline and rasagiline—and modulation of mitochondrial membrane potential. No human trials have been initiated, and vasicinone cannot be considered a treatment or preventive strategy for Parkinson's disease based on current evidence.

What is the difference between vasicinone and other alkaloids in Adhatoda vasica?

Vasicinone is one of several alkaloids found in Adhatoda vasica, with vasicine being the most abundant. While vasicine is the primary active alkaloid, vasicinone is its oxidized derivative and may contribute to the plant's respiratory and anti-inflammatory effects. The ratio and activity of these alkaloids can vary depending on plant part, growing conditions, and extraction methods used in supplements.

Is vasicinone safe for children or during pregnancy?

There is insufficient clinical data on vasicinone safety in children or during pregnancy, so supplementation should be avoided in these populations without medical supervision. Traditional use of Adhatoda vasica in respiratory support does not establish safety in vulnerable groups, as modern supplement concentrations may differ from historical preparations. Anyone considering vasicinone during pregnancy or for pediatric use should consult a healthcare provider first.

How strong is the current evidence for vasicinone's neuroprotective effects?

Current evidence for vasicinone's neuroprotective potential is limited to preclinical (laboratory and animal) studies examining oxidative stress modulation in Parkinson's disease models. No human clinical trials have been completed to confirm these effects in patients. While preclinical research is promising, it does not establish that vasicinone is effective or safe for neurodegenerative conditions in humans.

Vasicinone

Vasicinone is a quinazoline alkaloid derived primarily from Adhatoda vasica (Malabar nut) that acts as a bronchodilator by relaxing airway smooth muscle through phosphodiesterase inhibition and beta-adrenergic modulation. Its primary research applications center on respiratory support, anti-inflammatory activity, and emerging neuroprotective effects, though human clinical data remain scarce.

Category: Compound Evidence: 2/10 Tier: Emerging

Origin & History

Vasicinone is a quinazoline alkaloid primarily isolated from the leaves of Adhatoda vasica (Malabar nut tree) and Peganum harmala. It appears as a white crystalline powder with the molecular formula C₁₁H₁₀N₂O₂, typically extracted from plant material using standard alkaloid isolation procedures with solvents like ethanol.

Historical & Cultural Context

Vasicinone is a constituent of Adhatoda vasica leaves, which have been used in Ayurvedic medicine for centuries to treat respiratory conditions like cough and asthma. While the plant has extensive traditional use in Indian medicine systems, isolated vasicinone's specific historical use is not documented.

Health Benefits

• Bronchodilator effects for respiratory support (preclinical evidence only)
• Anti-inflammatory properties (limited to preclinical studies)
• Antitussive (cough suppressant) activity (preclinical evidence)
• Potential neuroprotective effects for Parkinson's disease via oxidative stress modulation (preclinical only)
• Traditional respiratory health support as part of Adhatoda vasica preparations (historical use)

How It Works

Vasicinone inhibits phosphodiesterase (PDE) enzymes, thereby elevating intracellular cyclic AMP (cAMP) levels in bronchial smooth muscle cells, which promotes relaxation and airway dilation. It also suppresses NF-κB signaling and reduces pro-inflammatory cytokine release—including TNF-α and IL-6—contributing to its anti-inflammatory profile. Additionally, vasicinone has been shown to modulate monoamine oxidase B (MAO-B) activity and attenuate oxidative stress markers such as reactive oxygen species (ROS), providing a proposed mechanism for its putative neuroprotective effects relevant to Parkinson's disease models.

Scientific Research

No human clinical trials, randomized controlled trials, or meta-analyses specifically on vasicinone were identified. Current research is limited to preclinical studies demonstrating bronchodilator, anti-inflammatory, antitussive, and potential neuroprotective effects.

Clinical Summary

The vast majority of evidence for vasicinone comes from in vitro cell studies and rodent models, with no large-scale randomized controlled trials conducted in humans as of current literature. Preclinical bronchodilation studies in guinea pig tracheal preparations demonstrated smooth muscle relaxation comparable in mechanism—though not potency—to theophylline, a known PDE inhibitor. Anti-inflammatory effects have been quantified in lipopolysaccharide-induced murine macrophage models showing 40–60% reductions in TNF-α and IL-6, but these findings have not been replicated in human subjects. Neuroprotective data stem from MPTP-induced Parkinson's mouse models showing reduced dopaminergic neuron loss, making any clinical extrapolation premature without Phase I or Phase II trial data.

Nutritional Profile

Vasicinone is a quinazoline alkaloid (molecular formula: C₁₁H₁₀N₂O₂, molecular weight: 202.21 g/mol) and is not a nutritional substance — it has no macronutrient, vitamin, or mineral profile. It is a bioactive secondary metabolite found primarily in Adhatoda vasica (Malabar nut) leaves, typically present at concentrations of approximately 0.05–0.3% dry weight of the leaf, often co-occurring with its reduced analog vasicine (peganine) at roughly 0.5–1.5% dry weight. Vasicinone is the oxidized (2,3-dehydro) derivative of vasicine. It is sparingly soluble in water and moderately soluble in organic solvents such as methanol, ethanol, and chloroform. Oral bioavailability data in humans is limited; preclinical pharmacokinetic studies suggest moderate absorption with relatively rapid hepatic metabolism. The compound acts primarily as a pharmacologically active alkaloid rather than a nutrient. In whole-leaf Adhatoda vasica preparations, vasicinone is accompanied by other quinazoline alkaloids (vasicine, vasicinol, deoxyvasicine), flavonoids, and essential oils, but the leaf itself provides negligible caloric, protein, fat, carbohydrate, fiber, vitamin, or mineral value at typical dosing levels. No Recommended Daily Intake or nutritional reference value exists. Bioavailability may be influenced by co-administration with vasicine (synergistic bronchodilatory effects noted in preclinical models) and by first-pass hepatic oxidation. Standardized extract concentrations used in research typically range from 1–10 mg/kg body weight in animal models; no established human equivalent dose has been validated in clinical trials.

Preparation & Dosage

No clinically studied dosage ranges are available as human trials have not been conducted. Standardized forms and dosing protocols have not been established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Vasicine, Adhatoda vasica extract, Tylophora indica, Glycyrrhiza glabra, Piper longum

Safety & Interactions

Vasicinone shares structural and pharmacological similarities with vasicine, and at higher doses both compounds have demonstrated uterotonic and potential abortifacient effects in animal studies, making use during pregnancy explicitly contraindicated. Because vasicinone inhibits PDE enzymes, concurrent use with other bronchodilators such as theophylline, aminophylline, or beta-agonists like albuterol could produce additive effects and increase the risk of tachycardia or hypotension. Potential MAO-B inhibitory activity raises a theoretical interaction risk with serotonergic medications, tyramine-rich foods, and other MAO inhibitors, though this has not been confirmed in human pharmacokinetic studies. No standardized safe dosage range has been established for isolated vasicinone in humans, and supplementation should be approached with caution and physician oversight.